Your browser is no longer supported. Please, upgrade your browser.
We’ve redesigned our maps and bubbles! Read more about the new features here. ×
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E13.91 EPS (ttm)7.49 Insider Own0.40% Shs Outstand1.50B Perf Week1.42%
Market Cap156.18B Forward P/E10.01 EPS next Y10.41 Insider Trans-23.90% Shs Float1.49B Perf Month-0.80%
Income12.10B PEG0.55 EPS next Q2.26 Inst Own85.20% Short Float3.56% Perf Quarter3.57%
Sales24.89B P/S6.27 EPS this Y306.10% Inst Trans-3.25% Short Ratio3.19 Perf Half Y-1.96%
Book/sh10.51 P/B9.91 EPS next Y9.00% ROA58.60% Target Price118.96 Perf Year24.32%
Cash/sh7.82 P/C13.32 EPS next 5Y25.20% ROE122.20% 52W Range63.50 - 116.83 Perf YTD10.53%
Dividend- P/FCF- EPS past 5Y39.10% ROI78.70% 52W High-10.82% Beta0.71
Dividend %- Quick Ratio2.90 Sales past 5Y28.80% Gross Margin84.80% 52W Low64.08% ATR2.42
Employees6100 Current Ratio3.20 Sales Q/Q134.40% Oper. Margin61.80% RSI (14)57.26 Volatility1.39% 2.29%
OptionableYes Debt/Eq0.00 EPS Q/Q373.90% Profit Margin72.30% Rel Volume0.40 Prev Close104.43
ShortableYes LT Debt/Eq0.00 EarningsFeb 03 AMC Payout0.00% Avg Volume16.63M Price104.19
Recom1.80 SMA201.88% SMA503.30% SMA2006.89% Volume6,691,202 Change-0.23%
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Feb-26-15 07:05PM  Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) Business Wire
06:51PM  Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV AP
03:45PM  Gilead Avoids Billions in U.S. Tax on Its $1,000-a-Pill Drug Bloomberg
03:19PM  Gilead dodges billions in taxes as money rolls in from hepatitis C drugs at San Jose Mercury News
03:14PM  Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV Business Wire
03:05PM  Omega Advisors opens a new position in Gilead Sciences Market Realist
12:51PM  Value hunting in the Nasdaq CNBC
11:10AM  Biotech Making A Comeback - Here Is One Stock to Watch Company Spotlight
11:01AM  Gilead Sciences: Despite Dividend, Still Room For Growth at Barrons.com
09:25AM  Short Sellers Increase Bets Against Biotech as Shares Continue to Rise at 24/7 Wall St.
Feb-25-15 04:11PM  GILEAD SCIENCES INC Files SEC form 10-K, Annual Report EDGAR Online
03:27PM  Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys Business Wire
10:38AM  Gilead & AbbVie: It Doesn't Matter Which Drug is Better, Just Who Will Pay at Barrons.com
09:56AM  13F Filings Takeaway: Own A Dirty Dozen at Forbes
Feb-24-15 05:00PM  Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25 Business Wire
03:39PM  Allergan, Inc. (AGN), HCA Holdings Inc (HCA), Gilead Sciences, Inc. (GILD) Among Healthcare Stocks That Billionaires Love at Insider Monkey
03:15PM  Failure of Anti-HIV Vaginal Gel Shows Difficulty of Prevention at Bloomberg
07:03AM  What's driving the Nasdaq? These 5 stocks CNBC
Feb-23-15 07:58PM  Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires 5 Hottest Biotech Picks at Insider Monkey
04:12PM  How Gilead Sales Have Grown Conspicuously? at Investopedia
11:56AM  Gilead Sciences: Uh Oh, AbbVie Might Be Doing Better Than We Thought at Barrons.com
11:17AM  Biotech on the rise; Analyst likes Gilead CNBC
11:06AM  Big pharma invests big money in research and development Market Realist
08:41AM  Mylan to Distribute Gilead's Hepatitis C Drugs in India at The Wall Street Journal
08:14AM  How Obamacare Pits Insurers Against The Medical Industry at Forbes
Feb-20-15 08:41PM  Overheard: Gilead Needs More Tracks at The Wall Street Journal
03:08PM  Gilead Sciences: How Strong are Hepatitis-C Sales? at Barrons.com
03:07PM  Gilead's One Track Bind at The Wall Street Journal
12:28PM  What it takes to be called big pharma Market Realist
12:00PM  Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog Zacks
08:30AM  FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Company Spotlight
Feb-19-15 02:54PM  10 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
Feb-18-15 02:08PM  Nasdaq names leading the way CNBC
12:01AM  Gilead's Pill Can Stop HIV. So Why Does Almost Nobody Take It? Bloomberg
Feb-17-15 05:55PM  CVS urges cost controls for new cholesterol drugs Reuters
02:15PM  AbbVie: Amgen Circa 2011? at Barrons.com
11:45AM  Why Gilead Sciences Doesn't Seem Too Worried About AbbVie's Hep-C Treatment at Barrons.com
09:41AM  Apple Inc. (AAPL), Microsoft Corporation (MSFT), and Intel Corporation (INTC): Bridgewater Associates Reveals Top Picks at Insider Monkey
Feb-13-15 04:41PM  Netflix, Amazon Lead Q4 With Biggest Earnings Beat at Investor's Business Daily
10:31AM  Gilead Sciences: Hepatitis-C Tracking at High End of Guidance, RBC Says at Barrons.com
Feb-12-15 01:30PM  AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Zacks
10:12AM  The Hepatitis C Scorecard: Gilead is Trouncing AbbVie, but at a Price at The Wall Street Journal
10:07AM  Are Sky-High Prices For New Drugs Justified? at Forbes
09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
08:54AM  Gilead agrees 41,000 eur hep-C drug price for 12 week treatment Reuters
08:44AM  Brookdale scales up in response to industry dynamics Market Realist
Feb-11-15 04:38PM  Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News Zacks
11:47AM  Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog Zacks
10:19AM  Gilead Sciences: 'Significant Reassurance to Skittish Investors' at Barrons.com
10:03AM  Hey Abbvie, Don't Start What You Can't Finish Yahoo Finance Contributors
07:54AM  JMP Securities Covers Mostly Good News From Pharma Pending More Visibility Benzinga
Feb-10-15 04:38PM  Gilead expects big increase in Europeans treated with hep C drug Reuters
11:10AM  Gilead Faces Sovaldi Patent Challenge in Europe by a Non-Profit Group at The Wall Street Journal
05:00AM  Gilead faces challenge to European patent on pricey hep C drug Reuters
Feb-09-15 05:00PM  Gilead Sciences to Present at Two Upcoming Investor Conferences Business Wire
03:38PM  Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News Zacks
03:21PM  [video]Jim Cramer Answers Twitter Questions on Coca-Cola, Yelp, Facebook, and More at TheStreet
12:24PM  Gilead Walloped by Lower Pricing View on Hepatitis C at Barrons.com
Feb-06-15 09:38PM  Gilead's Dividend Debut; GM Relents at Barrons.com
07:04PM  Tech Earnings Soar 17.3%, Largely Thanks To Apple Investor's Business Daily
05:47PM  Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog Zacks
05:21PM  Drug price wars 'drive value': Medical exec at CNBC
03:37PM  Gilead Sciences (GILD) Stock Lower Today After Credit Suisse Downgrade at TheStreet
03:23PM  Gilead Sciences, AbbVie and the End of the Hepatitis-C Trade at Barrons.com
03:19PM  Drug price battles CNBC
12:15PM  Credit Suisse Gives Up on Gilead, Sort Of at 24/7 Wall St.
09:34AM  Credit Suisse Downgrades Gilead Sciences, Sees Declining HCV Revenues Benzinga
09:11AM  Morning Movers: Frontier Communications Gains on Verizon Landline Purchase; Gilead Drops on Downgrade at Barrons.com
06:05AM  Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx at TheStreet
Feb-05-15 03:18PM  No, the Gilead-AbbVie Price War Won't Derail the Pharmaceutical Rally at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks
07:00AM  Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-04-15 07:28PM  Gilead's Harvoni Investor's Business Daily -8.16%
07:28PM  Gilead Investor's Business Daily
06:41PM  Gilead's deep discounts fuel investor worries about drug pricing Reuters
05:46PM  Best biotech plays CNBC
04:44PM  S&P 500 Growth Gets a Boost From A Few Notable Earnings Reports Yahoo Finance Contributors
04:36PM  Midweek Market Recap.. Yahoo Finance Contributors
03:47PM  Gilead Sciences: Look on the Bright Side? at Barrons.com
03:05PM  Competition, discount worries weigh on Gilead shares AP
01:55PM  Gilead to discount its pricey Sovaldi drug at MarketWatch
01:27PM  Gilead sinks on discounting worries at Financial Times
12:49PM  Gilead Down on Discounting News at The Wall Street Journal
12:37PM  Gilead Dislodges a Brick in the Biotech Wall of Worry Yahoo Finance Contributors
12:36PM  Safe biotech plays CNBC
12:15PM  What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean at The Wall Street Journal
12:13PM  Pricing wars heat up over hepatitis C drugs at CNBC
12:12PM  HCV Stocks Struggle As Gilead, Merck Face Headwinds at Investor's Business Daily
11:59AM  Gilead Sciences Getting Crushed On Mixed Results Benzinga
11:47AM  Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog Zacks
11:26AM  Drugmaker Merck posts spike in 4Q profit, beats forecasts AP
11:04AM  Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders at Bloomberg
10:58AM  Jim Cramer: Don't Bail on Biotech or Chipotle Mexican Grill at TheStreet
10:45AM  Gilead Dividend and Buyback Different From Amgens Strategy at 24/7 Wall St.
10:43AM  Stocks, Volume Get Mixed Start; Sony, Manhattan, Noah Spike at Investor's Business Daily
10:22AM  Will Dividend Investors Find Gilead? at Barrons.com
10:20AM  Humana's Medicare Business Booms But So Do Flu Costs at Forbes
10:14AM  Gilead Sciences: Hep-C Price War Takes Its Toll at Barrons.com
10:13AM  Gilead Tanks on Hep C Forecast: What Wall Street's Saying at TheStreet
09:22AM  Cramer's Mad Dash: GILD & CMG CNBC
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM